Additionally, combinatorial approaches using AXL inhibitors in conjunction with targeted agents against other dysregulated pathways in AML, such as FLT3 inhibitors or BCL-2 inhibitors, hold potential for overcoming therapeutic resistance. The gene discussed is FLT3; the disease is acute myeloid leukemia.